The A.M.IgA. Study is evaluating whether an investigational medication can help slow down the progression of IgA nephropathy (IgAN) by reducing how much of the defective IgA protein is produced in the body.
The study will involve up to 40 visits over the course of about 2 years and is divided into 2 year-long periods. Those who qualify will receive either the investigational medication or a placebo (a substance that looks like the investigational medication but contains no active ingredients), along with standard-of-care therapy.
Each year-long period includes 22 weeks of subcutaneous (under the skin) injections (weekly for 9 doses, then every other week for 7 doses), followed by a 30-week dosing-free phase. Those who complete the study may be eligible for a continuation study.
